TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06515613: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Sponsor: Context Therapeutics Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT06515613 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06515613 Rescue Dossier →